Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: strong software and services margins, new customer acquisitions, and a healthy cash position are positive. However, the cautious revenue guidance, increased tax expense, and lack of AI monetization in FY '26 are concerns. The Q&A highlighted uncertainties in guidance adjustments and macroeconomic factors, tempering optimism. These factors suggest a neutral stock price movement over the next two weeks.
Key Financial Performance
Total Revenue $24.3 million, an 8% increase year-over-year. Growth attributed to increases in both Software and Service segments.
Software Revenue Increased 9%, representing 60% of total revenue. Growth driven by Discovery revenue (19% increase) and Development revenue (12% increase).
Services Revenue Increased 8%, representing 40% of total revenue. Growth attributed to Development services (12% increase) and Commercialization services (1% decline).
Discovery Revenue Increased 19% for the quarter and 6% for the trailing 12-month period. Growth driven by ADMET Predictor.
Development Revenue Increased 12% for the quarter and 3% for the trailing 12-month period. Growth driven by GastroPlus and MonolixSuite.
Clinical Operations Revenue Declined 54% for the quarter and 58% for the trailing 12-month period. Decline attributed to reduced demand.
Gross Margin 66% total gross margin, up from 59% in the prior period. Software gross margin increased to 89% (from 81%), and Services gross margin increased to 33% (from 25%). Increase driven by higher software-related revenue and lower software-related costs.
Income Tax Expense $1.4 million, up from $0.4 million last year. Effective tax rate increased to 23% from 12%, due to less favorable jurisdictional earnings mix, increased GILTI impacts, and lower FDII benefits.
Cash and Short-term Investments $41.8 million, with no debt and strong free cash flow.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI Integration in Product Roadmap: Simulations Plus is embedding AI across its product roadmap to improve compute performance, interoperability, data management, automation of repetitive tasks, and accessibility of tools.
Strategic Collaboration Programs: The company announced collaborations with three large pharmaceutical companies to advance AI workflows in drug development using platforms like GastroPlus, MonolixSuite, ADMET Predictor, and Thales.
Global Market Conditions: Encouraging global market conditions supported by favorable pricing agreements, easing tariff concerns, and improved funding environments for customers.
Client Spending and Software Renewal Rates: Increased client spending with solid software renewal rates and strengthened service bookings.
Revenue Growth: Achieved $24.3 million in revenue for Q2 FY2026, with 8% growth overall, 9% growth in software revenue, and 8% growth in services revenue.
Gross Margin Improvement: Total gross margin increased to 66%, with software gross margin at 89% and services gross margin at 33%.
Client Metrics: 297 commercial clients with an average revenue per client of $124,000 and a 91% renewal rate for the quarter.
AI-Driven Ecosystem Transition: Transitioning from standalone modeling tools to an integrated AI-driven biosimulation ecosystem for drug development.
Sales Team Reorganization: Reorganizing sales team from product-focused selling to a regional account-based model to deepen client relationships and enhance cross-sell opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
AI-related competitive concerns: AI-related competitive concerns have impacted valuations across software-based business models, including biosimulation. There is a risk of disruption to certain software models due to AI advancements.
Decline in software renewal rates: Software renewal rates have declined, particularly among smaller biopharma and precommercial biotech companies, which could impact revenue stability.
Challenging early-stage biopharma market: The early-stage biopharma market has been challenging, leading to episodic demand and churn among smaller clients.
Tax rate increase: The effective tax rate for fiscal 2026 is expected to increase to 23%-25% from the previous expectation of 12%-14%, which could impact net income.
Regulatory and compliance risks: The company operates in regulated environments, and changes in regulatory guidance, such as NAMS, require adaptation and could pose compliance challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Fiscal 2026: Total revenue is expected to be between $79 million to $82 million, representing year-over-year revenue growth of 0% to 4%.
Revenue Guidance for Q3 2026: Revenue is anticipated to be between $20 million to $22 million.
Adjusted EBITDA Margin: For fiscal 2026, adjusted EBITDA margin is projected to be between 26% to 30%. For Q3 2026, adjusted EBITDA margin is expected to range from 27% to 33%.
Adjusted Diluted EPS: For fiscal 2026, adjusted diluted earnings per share is expected to range between $0.75 to $0.85. For Q3 2026, adjusted diluted EPS is projected to be between $0.20 to $0.27.
Effective Tax Rate: The effective tax rate for fiscal 2026 is now expected to be between 23% to 25%, revised from the previous expectation of 12% to 14%.
AI Integration and Strategic Collaboration: The company is advancing AI workflows across the drug development lifecycle through strategic collaborations with three large pharmaceutical companies. These programs will integrate AI agents into modeling workflows, enabling natural language interaction, automation of data processing, and coordination of simulations.
Software and Services Growth: The company is transitioning into an integrated AI-driven biosimulation ecosystem, enhancing cloud capabilities, AI-powered workflows, and interoperability to support drug development from discovery to commercialization.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details on the collaborations with the 3 large pharma customers announced recently?
A:The collaborations with the 3 large pharma customers have been ongoing for some time and are not new relationships. These collaborations focus on ensuring visibility into their needs and workflows to tailor AI capabilities to their environments. Financial components have been discussed, with at least one relationship already having a financial aspect. Long-term financial agreements are still under discussion.
Q:Are the new logos mentioned competitive conversions or entirely new customers?
A:The new logos are entirely new customers adopting the company's solutions for the first time. Some may be competitive conversions, but they are primarily smaller or startup companies initiating internal biosimulation capabilities.
Q:What is driving the sequential uptick in the commercial portion of the services backlog?
A:The uptick is driven by strong pipeline activity and service revenue delivery, particularly in the development space (75% of service business) and kinetic communications (25%). The proficiency acquisition has contributed to this growth, with cumulative performance through the midpoint of the year being strong.
Q:Where is the biggest opportunity for upselling among customers?
A:Opportunities exist at all levels, including moving single-product customers to two products and two-product customers to three. The Monolix product has shown strong growth and complements other offerings. The company has reorganized its business development to focus on client quotas rather than product quotas, which is expected to enhance cross-selling efforts.
Q:How does the company view its performance relative to its initial guidance for the year?
A:The company remains cautious despite strong momentum in the first half of the year. They are hesitant to adjust guidance upward due to macroeconomic and industry-specific uncertainties. They aim to avoid overreacting to short-term trends.
Q:What is driving the momentum in the industry, and how does it relate to NAMs and AI adoption?
A:Momentum is driven by broad support for biosimulation, in silico methodologies, and AI from regulatory bodies and pharma companies. While NAMs (non-animal methods) are on the horizon, the current momentum is more about internal AI implementation by pharma companies rather than external partnerships.
Q:How is the company progressing in cross-selling and reaching multiple buyers within client organizations?
A:The company is leveraging its modeling and simulation relationships to build connections with AI budget leaders within client organizations. The proficiency acquisition has opened new opportunities in clinical trial operations, and AI budgets within pharma companies present significant growth potential.
Q:What is the timeline for AI monetization, and what are the expectations?
A:AI monetization is not expected to contribute significantly in fiscal year '26. Discussions with collaborators are ongoing, and the company anticipates AI monetization to become a contributor in fiscal year '27.
Q:Are large AI companies like Google DeepMind clients of the company?
A:Yes, many large AI companies, including Google DeepMind, license some of the company's software. These companies primarily use the ADMET Predictor for property prediction and may adopt other solutions like GastroPlus and Monolix as they move into clinical development.
Q:What explains the relative decline in total projects year-over-year versus the increase in backlog?
A:The number of projects can vary based on the size and scope of individual projects. The increase in backlog reflects a strong pipeline and project closures ahead of actual performance.
Q:Will there be any shifts in the software solutions segment breakdown over the next year?
A:The software solutions segment breakdown is expected to remain stable, with potential incremental growth in the Monolix platform due to its strong adoption and cross-selling opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about adjusting guidance upward despite strong performance in the first half of the year. They cited macroeconomic and industry-specific uncertainties but did not provide specific details or clarity on the factors influencing their cautious approach.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Development
OConnor
Services margin
Software margin
application
approach
automation
backdrop
benefit
biopharma
client renewal
collaboration
company AI
concern
contribution service
contribution software
decade
deduction
development workflow
discovery
drug development
highlight
insight
logo retention
margin Services
methodology
month period
organization
period contribution
pipeline
plan
program
property prediction
service month
service trailing
software model
software product
software renewal
software trailing
trailing month
value engine
SLP Transcript
Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript
Unknown4-9
The earnings call reveals mixed signals: strong software and services margins, new customer acquisitions, and a healthy cash position are positive. However, the cautious revenue guidance, increased tax expense, and lack of AI monetization in FY '26 are concerns. The Q&A highlighted uncertainties in guidance adjustments and macroeconomic factors, tempering optimism. These factors suggest a neutral stock price movement over the next two weeks.
Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript
Unknown1-8
The earnings call summary presents a mixed outlook. While there is positive news about software performance peaking and MedCom exceeding expectations, challenges exist with clinical operations software revenue and tough comparisons. The Q&A section reveals cautious optimism with no change in guidance and AI integration showing promise. However, management's avoidance of specific details and the lack of new verticals or products in the near term suggest limited immediate catalysts. Consequently, the stock is likely to remain neutral over the next two weeks.
Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
Unknown12-1
The earnings call summary and Q&A session reveal a mixed outlook. Positive elements include stable fiscal year '26 guidance, potential growth from AI capabilities, and interest in acquisitions. However, challenges such as a significant drop in Pro-ficiency software revenue, cautious large pharma, and current renewal rates in the low to mid-80% range offset these positives. The lack of significant changes in guidance assumptions and the absence of major cancellations provide stability, but the overall sentiment remains neutral due to the balancing of positive and negative factors.
Simulations Plus, Inc. (SLP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-11
SLP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
